Oncternal Therapeutics Inc Stock Price, News & Analysis

Oncternal Therapeutics has appointed Pablo Urbaneja as Senior Vice President, Corporate Development, tasked with enhancing strategic planning and corporate initiatives. Previously, Urbaneja held a similar role at Coherus Biosciences, contributing to its biosimilars and immuno-oncology pipeline. He also has experience from McKinsey & Company. Oncternal has granted inducement awards to Urbaneja and Yao Wang, both involving options on shares, aimed at attracting talent as part of their growth strategy. The company continues to develop novel oncology therapies targeting unmet medical needs.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced an inducement award to Christopher Markey, its new Director of Program and Alliance Management, on June 1, 2021. This award consists of options to purchase 85,000 shares of common stock, having a 10-year term and an exercise price aligned with the closing stock price on the grant date. The options will vest over four years. This compensation was approved by the compensation committee, adhering to Nasdaq regulations, as an incentive for Markey to join the company.

Oncternal Therapeutics (Nasdaq: ONCT) announced a corporate overview presentation at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 am Eastern Time. Interested participants can register in advance through a provided link. Following the event, a replay of the presentation will be available on the company's Investors section of the website. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, including ongoing clinical trials for cirmtuzumab and TK216.

Oncternal Therapeutics (Nasdaq: ONCT) announced promising interim results from its Phase 1/2 study TK216-01, focusing on TK216 for relapsed or refractory Ewing sarcoma. Two patients achieved complete responses, remaining disease-free for over 24 and 14 months, respectively. The agent displayed a manageable safety profile with no unexpected toxicities. As of April 16, 2021, 68 patients were treated, showing a 9.7% objective response rate and a disease control rate of 45.2%. TK216 received multiple FDA designations, indicating its potential in treating unmet medical needs in oncology.

Oncternal Therapeutics (Nasdaq: ONCT) announced encouraging interim clinical data from the Phase 1/2 CIRLL clinical trial, evaluating cirmtuzumab combined with ibrutinib for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The objective response rate (ORR) was 83% for MCL patients, significantly higher than the historical rate of 66% for ibrutinib alone. The complete response (CR) rate reached 39%, with durability lasting 8-30+ months. Median progression-free and overall survival have not been reached. The safety profile remains consistent with ibrutinib, and enrollment continues.

Oncternal Therapeutics has appointed Salim Yazji, M.D., as Chief Medical Officer to advance its oncology pipeline. Dr. Yazji brings a wealth of experience in oncology drug development and regulatory strategy. His expertise is expected to enhance Oncternal's lead product candidate, cirmtuzumab, and its CAR-T therapy targeting ROR1. As part of his compensation, Oncternal granted Dr. Yazji options to purchase 425,000 shares, with an exercise price equal to the stock's closing price on his appointment date. This move is seen as a crucial step as the company heads toward key clinical trial phases.

Oncternal Therapeutics, Inc. reported promising interim results from a Phase 1b trial of cirmtuzumab combined with paclitaxel for HER2-negative breast cancer, showing a 57% objective response rate (ORR) compared to ~30% historical data. In preclinical studies, cirmtuzumab displayed activity in ovarian cancer cell lines. The company appointed Chase Leavitt as General Counsel and plans to present updates on cirmtuzumab and TK216 at the upcoming ASCO Annual Meeting. Financially, Oncternal reported a $5.9 million net loss for Q1 2021 and has $111.2 million in cash, expected to fund operations into 2023.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the grant of inducement awards to two new non-executive employees on May 3, 2021. Under the 2021 Employment Inducement Incentive Award Plan, the company issued options to purchase 219,400 shares at the closing price on the grant date. These options have a 10-year term and vest over four years. The awards comply with Nasdaq rules and aim to attract talent critical to Oncternal's oncology therapy development.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will announce its Q1 2021 financial results post-market on May 6, 2021. A webcast led by management will follow at 2:00 PM PT (5:00 PM ET) to discuss the results and provide a business update. Oncternal focuses on developing oncology therapies for critical medical needs, with ongoing clinical trials for cirmtuzumab and TK216. The company's pipeline targets significant cancer pathways, including a combination therapy for mantle cell lymphoma and a targeted inhibitor for Ewing sarcoma.